SYRE Shorts Hold Firm at 16% With an Activist on the Register

Short sellers have built a substantial position in SYRE ahead of Thursday's quarterly results. Around 16.2% of Spyre Therapeutics' free float is currently sold short, a level that has held remarkably steady over the past month, drifting only 0.6% higher across October. The past week saw a modest 3.2% reduction in shares short, though the absolute count remains near 12.5 million shares. Borrow costs have eased alongside that trim, falling 18.5% week-on-week to 0.46%, and availability is generous at 548%, meaning shares are plentiful to borrow relative to what is already lent out. Options positioning adds texture: the put/call ratio of 2.36 is modestly above its 20-day average of 2.30, but well within one standard deviation, so options traders are running a structurally defensive book rather than making a fresh bearish bet ahead of this print.

The analyst community has been adding coverage into this period. JP Morgan initiated at Overweight with a $110 target in October, and UBS followed with a Buy and $120 target shortly after. BTIG has held its Buy rating and $121 target through multiple reiterations. The mean consensus target of $122.53 sits about 23% above Monday's close of $99.27, implying the Street sees material upside even after a 6.5% gain over the past month. The bull case centres on Spyre's three proprietary antibodies, anti-α4β7, anti-TL1A, and anti-IL-23, each with clinical proof-of-concept, and a dosing schedule of Q3M to Q6M that could differentiate the platform in inflammatory bowel disease and hidradenitis suppurativa. SPY003 delivered a statistically significant 10.0-point RHI improvement and 20% clinical remission in 44 treated patients, while SPY001 has drawn best-in-class comparisons. The sceptical view is straightforward: no approved product, regulatory timelines are unpredictable, and the company will need repeated capital raises to reach commercialization. Deutsche Bank trimmed its target from $135 to $127 in late August while keeping Buy, a sign that even supportive analysts recalibrated after the most recent results.

One name on the shareholder register warrants attention. Peter Evan Harwin filed a Schedule 13D on SYRE, an activist-designated filing, and his stake stands at 9.99% of the class as of an October 9 amendment, unchanged from the prior filing. A 13D signals an intent beyond passive investment. Paradigm BioCapital Advisors LP filed a fresh Schedule 13G in October disclosing a 5.1% stake, while FMR (Fidelity) remains the largest institutional holder at 14.8% and added over 1.2 million shares in the most recent period. BlackRock and T. Rowe Price also added during Q3. As a caveat, 13D/G positions are event-driven disclosures around the 5% threshold and are stated as of last filing; holders who drop below 5% may not file again. On the insider side, the CEO sold approximately $1.4 million in shares on October 1, entirely under a pre-arranged 10b5-1 plan, reducing the signal value of those sales.

SYRE gained 4% on Monday while most of its closest peers fell. RLAY dropped 5.8% on the day and MLTX shed 2.6%, leaving SYRE ahead of the peer median by a wide margin over the session, though the stock's 0.2% weekly gain still trails the peer median of 4.7%. Wikipedia page-view data, tracked by ORTEX Alt Data, registered a z-score of 4.6 against Spyre's own 90-day history as of mid-October, pointing to a sharp spike in retail attention around that period. The print on November 6 will test whether the pipeline narrative that has sustained a 16% short position for months is durable, or whether updated clinical and financial disclosures shift the balance between conviction on either side.